Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
收盘时
US$9.28
+US$0.11 · +1.20%
盘后
US$9.28
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
日内区间
当前US$9.28
52周区间
当前US$9.28
盘中时间采用ET。市场数据可能有所延迟。
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
日内区间
当前US$9.28
52周区间
当前US$9.28
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8.22亿 USD | 7.99亿 USD | 7.47亿 USD | 4.61亿 USD | 4.64亿 USD |
| 销货成本 | 2.71亿 USD | 2.54亿 USD | 2.6亿 USD | 1.24亿 USD | 1.15亿 USD |
| 毛利 | 5.52亿 USD | 5.46亿 USD | 4.86亿 USD | 3.37亿 USD | 3.5亿 USD |
| 研究与开发 | 5711.2万 USD | 7364.3万 USD | 8023.1万 USD | 4906.5万 USD | 4962.1万 USD |
| 销售、一般及管理费用 | 4.56亿 USD | 5.33亿 USD | 5.3亿 USD | 3.09亿 USD | 2.91亿 USD |
| 营业费用 | 6.2亿 USD | 6.31亿 USD | 6.25亿 USD | 3.5亿 USD | 3.58亿 USD |
| 利息支出 | 1748.8万 USD | 2963.1万 USD | 863.1万 USD | 128.8万 USD | 183.7万 USD |
| 折旧和摊销 | 8325.5万 USD | 7596.2万 USD | 6056.1万 USD | 3207.5万 USD | 3309.6万 USD |
| 营业利润 | −6847.1万 USD | −8461.9万 USD | −1.39亿 USD | −1326.8万 USD | −831.5万 USD |
| 净利润 | −9219.2万 USD | −1.26亿 USD | −1.51亿 USD | −1974.9万 USD | −3837.9万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$13.40
上涨空间 44.40%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1140.71万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM957.91万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF443.44万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO218.51万0.01%180亿 USD0.06%US$112.27-0.35%
Dimensional - US Small Cap ETFDFAS196.92万0.01%338.69亿 USD0.31%US$78.17-0.23%
Schwab U.S. Small-Cap ETFSCHA194.24万0.01%218.24亿 USD0.03%US$32.66-0.40%
iShares U.S. Medical Devices ETFIHI184.95万0.05%35.74亿 USD0.37%US$52.79+2.03%
Fidelity Enhanced Small Cap ETFFESM148.4万0.02%64.1亿 USD0.28%US$45.24-0.48%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Vanguard Russell 2000 ETFVTWO
Dimensional - US Small Cap ETFDFAS
Schwab U.S. Small-Cap ETFSCHA
iShares U.S. Medical Devices ETFIHI
Fidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。